ES2149761T3 - Derivado de piridazinona. - Google Patents

Derivado de piridazinona.

Info

Publication number
ES2149761T3
ES2149761T3 ES91907712T ES91907712T ES2149761T3 ES 2149761 T3 ES2149761 T3 ES 2149761T3 ES 91907712 T ES91907712 T ES 91907712T ES 91907712 T ES91907712 T ES 91907712T ES 2149761 T3 ES2149761 T3 ES 2149761T3
Authority
ES
Spain
Prior art keywords
piridazinone
derived
salt
vasodilatory
cardiotonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907712T
Other languages
English (en)
Spanish (es)
Inventor
Keizo Tanikawa
Akira Saito
Takashi Matsumoto
Ryozo Sakoda
Nobutomo Tsuruzoe
Ken Shikada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Application granted granted Critical
Publication of ES2149761T3 publication Critical patent/ES2149761T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES91907712T 1990-04-25 1991-04-19 Derivado de piridazinona. Expired - Lifetime ES2149761T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10991490 1990-04-25

Publications (1)

Publication Number Publication Date
ES2149761T3 true ES2149761T3 (es) 2000-11-16

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907712T Expired - Lifetime ES2149761T3 (es) 1990-04-25 1991-04-19 Derivado de piridazinona.

Country Status (17)

Country Link
US (3) US5202323A (OSRAM)
EP (1) EP0482208B1 (OSRAM)
JP (1) JPH07107055B2 (OSRAM)
KR (1) KR970002876B1 (OSRAM)
AT (1) ATE194835T1 (OSRAM)
AU (1) AU634655B2 (OSRAM)
CA (1) CA2053863C (OSRAM)
DE (1) DE69132329T2 (OSRAM)
DK (1) DK0482208T3 (OSRAM)
ES (1) ES2149761T3 (OSRAM)
GR (1) GR3034331T3 (OSRAM)
HU (1) HU208124B (OSRAM)
RU (1) RU2054004C1 (OSRAM)
TW (1) TW204348B (OSRAM)
UA (1) UA27031A1 (OSRAM)
WO (1) WO1991016314A1 (OSRAM)
ZA (1) ZA913134B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053863C (en) * 1990-04-25 1996-10-29 Keizo Tanikawa Pyridazinone derivatives
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
CA2170637C (en) * 1993-09-06 2005-01-25 Itaru Shigehara Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
TW326041B (en) * 1993-12-16 1998-02-01 Nippon Nouyaku Kk Pyridazinone derivatives, their production process and their use for inhibition of platelet aggregation
CN1049892C (zh) * 1994-01-25 2000-03-01 日产化学工业株式会社 哒嗪酮衍生物及其盐,其制造方法,及抗血小板医药组合物
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
SI0907650T1 (en) 1996-06-27 2003-06-30 Janssen Pharmaceutica N.V. N- 4-(heteroarylmethyl)phenyl)-heteroarylamines
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
JP4352613B2 (ja) * 1997-08-28 2009-10-28 日産化学工業株式会社 血管新生促進剤及び血管新生作用増強剤
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
PT1123704E (pt) * 1998-09-01 2004-10-29 Nissan Chemical Ind Ltd Agente terapeutico para a estenose da cauda equina
CZ20012020A3 (cs) * 1998-12-07 2001-10-17 Nissan Chemical Industries, Ltd. Činidlo pro léčbu erektilní dysfunkce
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
WO2002085897A1 (en) * 2001-04-05 2002-10-31 Alangudi Sankaranarayanan Heterocyclic compounds for aging-related and diabetic vascular complications
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
CA2447619A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for accelerating bone fracture healing
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005023241A1 (en) * 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
KR20060125816A (ko) * 2003-12-26 2006-12-06 닛산 가가쿠 고교 가부시키 가이샤 호중구증다 억제제
JP4783152B2 (ja) * 2004-02-09 2011-09-28 日産化学工業株式会社 血管内膜肥厚抑制薬
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010074090A1 (ja) 2008-12-25 2010-07-01 日産化学工業株式会社 ピリダジン-3(2h)-オン化合物塩酸塩の結晶及びその製造方法
BRPI1015135B1 (pt) 2009-06-29 2021-08-03 Incyte Holdings Corporation Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2535048A4 (en) 2010-02-12 2013-08-14 Taisho Pharmaceutical Co Ltd PREPARATION WITH DELAYED RELEASE
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
DK3513793T3 (da) 2011-09-02 2021-04-26 Incyte Holdings Corp Heterocyclylaminer som pi3k-inhibitorer
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN105979959B (zh) 2013-08-09 2021-11-30 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
CA2922943A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
MX373232B (es) 2015-02-27 2020-05-08 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación.
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
MA52761A (fr) 2018-06-01 2021-04-14 Incyte Corp Schéma posologique destiné au traitement de troubles liés à la pi3k
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
JPH0641455B2 (ja) * 1984-12-10 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
EP0220044B1 (en) * 1985-10-17 1991-01-30 Smith Kline & French Laboratories Limited 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
CA2053863C (en) * 1990-04-25 1996-10-29 Keizo Tanikawa Pyridazinone derivatives

Also Published As

Publication number Publication date
JPH07107055B2 (ja) 1995-11-15
KR970002876B1 (ko) 1997-03-12
HUT60253A (en) 1992-08-28
EP0482208A4 (en) 1992-10-07
JPH07107055B1 (OSRAM) 1995-11-15
WO1991016314A1 (en) 1991-10-31
DE69132329D1 (de) 2000-08-24
DK0482208T3 (da) 2000-09-18
CA2053863A1 (en) 1991-10-26
EP0482208B1 (en) 2000-07-19
EP0482208A1 (en) 1992-04-29
KR920701169A (ko) 1992-08-11
US5202323A (en) 1993-04-13
TW204348B (OSRAM) 1993-04-21
RU2054004C1 (ru) 1996-02-10
US5318968A (en) 1994-06-07
US5314883A (en) 1994-05-24
HU208124B (en) 1993-08-30
AU7651191A (en) 1991-11-11
AU634655B2 (en) 1993-02-25
GR3034331T3 (en) 2000-12-29
ZA913134B (en) 1992-04-29
ATE194835T1 (de) 2000-08-15
DE69132329T2 (de) 2000-11-30
HU913497D0 (en) 1992-01-28
CA2053863C (en) 1996-10-29
UA27031A1 (uk) 2000-02-28

Similar Documents

Publication Publication Date Title
ES2149761T3 (es) Derivado de piridazinona.
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
AU7815791A (en) Heterocyclene derivatives
DK0807633T3 (da) Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
FI905280A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivista bentsopyridopiperidiini-, piperidylideeni- ja -piperatsiiniyhdistettä
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
AP9701041A0 (en) Pyridylpyrrole compounds.
HUT62893A (en) Process for producing substituted pyrimidine derivatives and pharmaceutical compositions comprising such compounds as active ingredient
AU7436691A (en) Novel 2,9-disubstituted-4H-pyrido(1,2-a)pyrimidin-4-ones
GB9601722D0 (en) Heterocyclic derivatives
NO173444C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 4-(4'- fluorfenyl-)-tienopyridin-derivater
ZA979647B (en) Heterocyclic compounds, compositions and uses.
NO910904D0 (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
ZA979650B (en) Heterocyclic compounds, compositions and uses.
ZA979645B (en) Heterocyclic compounds, compositions and uses.
DE3372772D1 (en) Quinazolinone derivatives, process for their preparation and their use in medicaments
ATE10934T1 (de) Peptid, verfahren zu dessen herstellung und dessen verwendung.
SE9304065D0 (sv) New compound

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 482208

Country of ref document: ES